e-learning
resources
ERJ
2014
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Negative clinical trials in sarcoidosis: failed therapies or flawed study design?
Moller David R.
Source:
Eur Respir J 2014; 44: 1123-1126
Journal Issue:
November
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Moller David R.. Negative clinical trials in sarcoidosis: failed therapies or flawed study design?. Eur Respir J 2014; 44: 1123-1126
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Pulmonary sarcoidosis
Definition and history of sarcoidosis
ERS clinical practice guidelines on treatment of sarcoidosis
Related content which might interest you:
Placebo effects in pharmaceutical clinical trials in bronchiectasis: an EMBARC study
Source: Virtual Congress 2020 – New investigations of bronchiectasis and non-tuberculous mycobacteria
Year: 2020
Do the current endpoints in IPF clinical trials allow good regulatory decisions to be made?
Source: International Congress 2014 – Ceremony for the ERS Rare Pulmonary Disease Research Award 2014 followed by the symposium "Challenges in endpoints for rare lung diseases"
Year: 2014
New clinical research strategies in thoracic oncology: clinical trial design, adaptive, basket and umbrella trials, new end-points and new evaluations of response
Source: Eur Respir Rev 2014; 23: 367-378
Year: 2014
The future of translational lung cancer research: from classical randomised controlled trials to innovative platform trials
Source: International Congress 2018 – New drugs, strategies and research designs for advanced non-small cell lung cancer
Year: 2018
Missing data in IPF trials: do not let methodological issues undermine a major therapeutic breakthrough
Source: Eur Respir J 2015; 46: 607-614
Year: 2015
Effectiveness
versus
efficacy trials in COPD: how study design influences outcomes and applicability
Source: Eur Respir J, 51 (2) 1701531; 10.1183/13993003.01531-2017
Year: 2018
A non-interventional observational trial to study the COPD treatment choices in routine clinical practice in Bulgaria
Source: International Congress 2016 – COPD diagnosis and management
Year: 2016
Does pulmonary rehabilitation work in clinical practice? A review on selection and dropout in randomised controlled trials on pulmonary rehabilitation
Source: Annual Congress 2010 - Outcomes and predictors of the sucess of pulmonary rehabilitation in chronic respiratory disease
Year: 2010
What is the scientific and clinical rationale? Triple therapy in COPD patients
Source: Virtual Congress 2021 – Linking scientific mechanisms to recent clinical therapeutic advances in airway disease: why, who, when and what?
Year: 2021
Do patients with cystic fibrosis participating in clinical trials demonstrate placebo response ? A meta-analysis.
Source: International Congress 2019 – Advances in care and monitoring of cystic fibrosis
Year: 2019
Preschool asthma - have randomised controlled trials provided clarity on management?
Source: International Congress 2018 – Infectious agents and childhood asthma
Year: 2018
Adapting asthma clinical trials in response to the COVID-19 pandemic - the BenRex study design
Source: Virtual Congress 2021 – Severe asthma: evaluation using patient-reported outcome measures (PROMs) and biomarkers, comorbidities and treatments
Year: 2021
Efficacy and safety of new drugs for M/XDR-TB: what have we learned from observational studies?
Source: International Congress 2019 – Recent developments and future perspectives in the diagnosis and treatment of tuberculosis
Year: 2019
Clinical trials in idiopathic pulmonary fibrosis: a word of caution concerning choice of outcome measures
Source: Eur Respir J 2005; 26: 755-758
Year: 2005
How to treat IPF: lessons from the NIH-IPF-Net treatment trials
Source: International Congress 2014 – Ceremony for the ERS Idiopathic Pulmonary Fibrosis Research Award 2014 - Hot Topic: "Understanding and treating idiopathic pulmonary fibrosis (IPF) in the 21st century"
Year: 2014
Late-breaking abstract: The effects of roxithromycin as anti-inflammatoy agent on clinical outcomes in patient with bronchiectasis: A double blinded randomized controlled study
Source: Annual Congress 2011 - Late-Breaking Abstracts Session: New treatments and targets for airway disease
Year: 2011
Phase three studies of biologics for severe asthma: could do better?
Source: Eur Respir J, 50 (3) 1701108; 10.1183/13993003.01108-2017
Year: 2017
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept